Curaleaf (OTCMKTS:CURLF) Shares Gap Up – Still a Buy?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) gapped up before the market opened on Friday . The stock had previously closed at $2.7580, but opened at $3.07. Curaleaf shares last traded at $2.94, with a volume of 111,595 shares.

Analyst Ratings Changes

A number of brokerages have weighed in on CURLF. Canaccord Genuity Group upgraded shares of Curaleaf to a “strong-buy” rating in a research report on Thursday, October 9th. Atb Cap Markets raised Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 2nd. ATB Capital upgraded Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Finally, Alliance Global Partners restated a “buy” rating on shares of Curaleaf in a report on Monday, December 22nd. Two research analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the stock. According to MarketBeat, Curaleaf currently has a consensus rating of “Strong Buy”.

Curaleaf Price Performance

The stock has a fifty day moving average of $2.73 and a 200-day moving average of $2.30. The company has a quick ratio of 0.71, a current ratio of 1.47 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -8.97 and a beta of 0.77.

Curaleaf (OTCMKTS:CURLF) last released its earnings results on Wednesday, November 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. On average, equities research analysts predict that Curaleaf Holdings, Inc. will post -0.25 EPS for the current fiscal year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.